Inhibikase Therapeutics, Inc.
IKT · Biological Products, (No Diagnostic Substances) · 132.0M shares · +9%/yr ↑ shares · EDGAR filings ↗
Reference price $1.45 · est. market cap ~$191M — last insider purchase, 2025-11-21 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — clinical-stage biotech, very cash-rich.
Strengths
- Liquidity — current ratio 21.7 (95th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Cash burnNegative free cash flow (-27.8M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Strong balance sheetStrong balance sheet — $218M cash & investments, ~31 quarters of runway
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
- New fund positionNotable fund(s) opened this quarter: RENAISSANCE TECHNOLOGIES LLC
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-27.9%
Return on assets
-26.6%
Current ratio
21.7×
Free cash flow
-$28M
Tangible book value
$173M
Cash & investments
$218M
Cash runway
31q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-21 | Aurentz Vincent | Disposition | 255K | — |
| 2026-02-21 | Cabell Christopher | Disposition | 338K | — |
| 2026-02-21 | Munshi Amit | Disposition | 19K | — |
| 2025-11-21 | Sands Capital Life Sciences Pulse Fund II, L.P. | Buy | 2.1M | $1.45 |
| 2025-02-21 | Munshi Amit | Grant | 57K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 10-Q | 2026-05-12 | 2026-03-31 | 0001193125-26-219641 ↗ |
| 8-K | 2026-05-12 | 2026-05-12 | 0001193125-26-219610 ↗ |
| 8-K | 2026-04-07 | 2026-04-07 | 0001193125-26-144582 ↗ |
| 10-K | 2026-03-26 | 2025-12-31 | 0001193125-26-126371 ↗ |
| 8-K | 2026-03-26 | 2026-03-26 | 0001193125-26-126322 ↗ |
| 8-K | 2025-12-19 | 2025-12-19 | 0001193125-25-326916 ↗ |
| 8-K | 2025-11-21 | 2025-11-20 | 0001193125-25-291443 ↗ |
| 8-K | 2025-11-20 | 2025-11-20 | 0001193125-25-289768 ↗ |
| 8-K | 2025-11-14 | 2025-11-14 | 0001193125-25-283075 ↗ |
| 10-Q | 2025-11-14 | 2025-09-30 | 0001193125-25-283169 ↗ |
| 8-K | 2025-08-14 | 2025-08-14 | 0001193125-25-180889 ↗ |
| 10-Q | 2025-08-14 | 2025-06-30 | 0001193125-25-180899 ↗ |